Optimizing Cough Rehabilitation Through Combined Cough Skill Training and Transcutaneous Spinal Cord Stimulation (Optimizing Cou)
The goal of this clinical trial is to evaluate the effects of combining cough training with low-level electrical stimulation to the neck (tsDCS) in healthy adults and adults with neurological diseases. The main questions it aims to answer are:
- Is using tsDCS during cough training safe, tolerable, and acceptable to participants?
- What tsDCS settings are most effective for pairing with cough training? Researchers will compare sham stimulation with active tsDCS to see if tsDCS enhances cough gains. Before and after each testing session, participants will complete breathing, coughing, and respiratory-strength training.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Purpose and Background People with neurodegenerative diseases frequently experience reduced cough function (hypotussia) and swallowing difficulties (dysphagia), which negatively impact quality of life and increase the risk of pneumonia, a leading cause of death in these populations. While behavioral exercises like cough training can help improve airway protection, people with these diseases often struggle to perform them with the high intensity required to trigger lasting brain and nerve adaptation (neuroplasticity).
To overcome this limitation, this pilot study investigates a novel, non-invasive combinatorial approach: pairing Cough Skill Training (CST) with transcutaneous spinal direct current stimulation (tsDCS) applied to the neck. The theory is that spinal stimulation enhances communication between the brain and muscles, optimizing the outcomes of training. Because this combined intervention has not been tested before, this initial research aims to establish its overall feasibility and compare different stimulation settings in healthy adults before future translation to clinical patient populations.
Study Design and Methods This study is an initial pilot trial utilizing a randomized crossover design involving 16 healthy adult participants aged 40 to 85 years with normal respiratory function.
- Screening & Familiarization (Visit 1): Participants undergo baseline screening, including health history reviews and spirometry (pulmonary function testing). They are also familiarized with the testing and training activities.
- Intervention Sessions: Across separate intervention visits separated by a 6-week washout period, participants receive 20 minutes of neck-based tsDCS paired with CST. During active stimulation, current is delivered continuously, whereas sham stimulation provides brief ramping periods without sustained current. CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).
- Assessments: Researchers record vital signs, breathing tests, airway occlusions (to measure drive to breathe), maximum respiratory pressure tests. Exploratory measures, such as saliva swallowing patterns and how long participants can produce a vowel sound, are also tracked.
Aims:
- Aim 1: Feasibility and acceptability will be evaluated by the participants' ability to complete all training tasks simultaneously with stimulation, scores from the Acceptability of Intervention Measure (AIM), participant ability to blind/detect sham versus active treatment, and perceived exertion, task difficulty, and stimulation intensity ratings.
- Aim 2: Cough and respiratory performance will be measured by the change in cough peak expiratory flow rate (PEFR) from baseline, along with CST performance accuracy, other cough, resting breathing, and respiratory strength parameters.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: May Smith-Hublou, PhD, SLP
- Phone Number: 352-273-6855
- Email: maysmith@ufl.edu
Study Contact Backup
- Name: Barbara K Smith, PhD, PT
- Phone Number: 352-294-5315
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
Contact:
- May Smith-Hublou, PhD
- Phone Number: 352-273-6855
- Email: maysmith@ufl.edu
-
Principal Investigator:
- May Smith-Hublou, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Forced vital capacity (FVC) ≥ 80% predicted based on age/sex
Exclusion Criteria:
- neurological disease
- respiratory disease including acute respiratory infection with cough during past week
- Pregnancy
- metallic implants in the spine
- cardiac pacemaker
- use of sodium channel blockers, calcium channel blockers, and/or NMDA receptor antagonists
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Sham Comparator: Sham Stimulation
Transcutaneous spinal cord stimulation at reduced intensity, lasting 1 minute at the beginning and end of a 20-minute session. |
CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak). Transcutaneous spinal cord stimulation at reduced intensity, lasting 1 minute at the beginning and end of a 20-minute session. |
|
Experimental: Cathodal Stimulation
Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes. |
CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak). Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes. |
|
Experimental: Anodal Stimulation
Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes. |
CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak). Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Completion of training tasks with simultaneous stimulation
Time Frame: During training
|
Measured as percentage of sessions in which both interventions can be completed simultaneously. |
During training
|
|
Peak Cough Flow
Time Frame: Baseline, immediate post-single-treatment measurement
|
The highest rate of airflow generated during a volitional cough |
Baseline, immediate post-single-treatment measurement
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acceptability of Intervention Measure (AIM)
Time Frame: Immediate post-single-treatment measurement
|
Participants will rate favorability of treatment procedures. This scale consists of 4 items rating acceptability using a 1-5 Likert Scale, with a combined total score range of 4-20. A score of 1 represents "completely disagree," and a score of 5 represents "completely agree." Thus, a higher score reflects a more favorable experience. |
Immediate post-single-treatment measurement
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Airway occlusion pressure (P0.1)
Time Frame: Baseline vs immediate post-single-treatment
|
The change in air pressure at the opening of the airway (mouth and nose) in the first 100 ms of a breath. This estimates neural drive to breathe. |
Baseline vs immediate post-single-treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: May Smith-Hublou, PhD, University of Florida
Publications and helpful links
General Publications
- Nierat MC, Similowski T, Lamy JC. Does trans-spinal direct current stimulation alter phrenic motoneurons and respiratory neuromechanical outputs in humans? A double-blind, sham-controlled, randomized, crossover study. J Neurosci. 2014 Oct 22;34(43):14420-9. doi: 10.1523/JNEUROSCI.1288-14.2014.
- Delucenay-Clarke R, Nierat MC, Frugiere A, Similowski T, Cayetanot F, Bodineau L. Direct current stimulation as a non-invasive therapeutic alternative for treating autonomic or non-autonomic neurological disorders affecting breathing. Clin Auton Res. 2024 Aug;34(4):395-411. doi: 10.1007/s10286-024-01055-y. Epub 2024 Aug 12.
- Clark DJ, Hawkins KA, Winesett SP, Cox BA, Pesquera S, Miles JW, Fuller DD, Fox EJ. Enhancing Locomotor Learning With Transcutaneous Spinal Electrical Stimulation and Somatosensory Augmentation: A Pilot Randomized Controlled Trial in Older Adults. Front Aging Neurosci. 2022 Mar 2;14:837467. doi: 10.3389/fnagi.2022.837467. eCollection 2022.
- Borders JC, Villarreal-Cavazos K, Huber JE, Quinn L, Keller B, Troche MS. Enhancing Cough Motor Learning in Parkinson's Disease Through Variable Practice During Skill Training. Mov Disord Clin Pract. 2024 Dec;11(12):1500-1515. doi: 10.1002/mdc3.14218. Epub 2024 Oct 8.
- Benussi A, Cantoni V, Grassi M, Libri I, Cotelli MS, Tarantino B, Datta A, Thomas C, Huber N, Karkkainen S, Herukka SK, Haapasalo A, Filosto M, Padovani A, Borroni B. Cortico-spinal tDCS in amyotrophic lateral sclerosis: A randomized, double-blind, sham-controlled trial followed by an open-label phase. Brain Stimul. 2023 Nov-Dec;16(6):1666-1676. doi: 10.1016/j.brs.2023.11.008. Epub 2023 Nov 15.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB202600626
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Participant data that underlie the results reported in this article after deidentification.
IPD Sharing Time Frame
9 months and ending 36 months following article publication.
IPD Sharing Access Criteria
Investigators whose proposed use of the data has been approved by an independent review committee.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.